Volition developing Covid-19 triage test

Our client Volition RX may soon be helping in the fight against the Covid-19 pandemic.

Excitingly Volition have discovered that the patented technology behind their cancer tests may well also be used to develop a COVID-19 Triage test.  It is hoped that this test will tell doctors if a patient with Covid is likely to go on and develop serious symptoms or complications.  Further trials are continuing with the aim of producing a CE-marked product for this by the end of 2020. 

We have been helping them update their investors and the world at large about the possible breakthrough.

Commenting on the results, corresponding author Professor Stefan Holdenrieder, Director of the Institute of Laboratory Medicine, German Heart Center, Munich, Germany said, “We tested two independent cohorts of COVID-19 positive patients with quantitative nucleosome immunoassays and found that nucleosomes were highly elevated in plasma of severe COVID-19 patients relative to healthy control subjects and that both histone 3.1 variant and citrullinated nucleosomes increased with disease severity. Given that the highest levels of nucleosomes were found in patients requiring artificial ventilation or extracorporeal oxygenation, we believe that nucleosomes could serve as a guiding biomarker for disease severity in COVID-19 positive patients.”

Cameron Reynolds, Chief Executive Officer of Volition commented, “Nu.QTM has shown correlation with more severe COVID-19 cases implying strong prognostic potential, and we are now focused on the completion of larger longitudinal studies that would be needed to support a potential COVID-19 product launch. If we continue to see positive results in these longitudinal studies, we aim to have a CE-marked product available on multiple platforms in 2020 and will look to launch a low-cost product that could be used in any laboratory worldwide as soon as possible thereafter.”

To read more about it and see our film click here.